Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

NCT01440088 is registered in ClinicalTrials.gov with Threshold Pharmaceuticals as lead sponsor.

NCT NCT01440088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01440088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Lead sponsor
Threshold Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2011
Completion date
May 31, 2016
Enrollment
640 (actual)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma